Evidence map›Paper›PMID 40962940›Full record

ArticleEMBO molecular medicine2025

Impaired migration and lung invasion of human melanoma by a novel small molecule targeting the transmembrane domain of death receptor p75

Vanessa Lopes-Rodrigues, Samuel A Nyantakyi, Xueqing Lun, Xueyan Han, Jianbo Zhang, Ajeena Ramanujan, Shuhailah Salim, Michael Saleeb, Liane Babes, Angela Z Chou and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Amelioration of Symptomatic Alzheimer's Disease after Selective Impairment of p75The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Vanessa Lopes-RodriguesDepartment of Physiology and Life Sciences Institute, National University of Singapore, Singapore, 117456, Singapore.ORCID http://orcid.org/0000-0002-0084-943X
Samuel A NyantakyiDepartment of Neuroscience, Karolinska Institute, Stockholm, 17177, Sweden.ORCID http://orcid.org/0000-0002-9890-6921
Xueqing LunArnie Charbonneau Cancer Institute, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, T2N 1N4, Canada.
Xueyan HanCollege of Biological Sciences, China Agricultural University, 100193, Beijing, China.ORCID http://orcid.org/0009-0002-1756-7882
Jianbo ZhangLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Ajeena RamanujanDepartment of Physiology and Life Sciences Institute, National University of Singapore, Singapore, 117456, Singapore.ORCID http://orcid.org/0000-0002-6843-5372
Shuhailah SalimDepartment of Physiology and Life Sciences Institute, National University of Singapore, Singapore, 117456, Singapore.ORCID http://orcid.org/0009-0005-9456-3481
Michael SaleebDepartment of Neuroscience, Karolinska Institute, Stockholm, 17177, Sweden.
Liane BabesLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Angela Z ChouInterdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 201203, Shanghai, China.
Lingyu DuInterdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 201203, Shanghai, China.ORCID http://orcid.org/0009-0002-7395-5476
Siyi DongInterdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 201203, Shanghai, China.
James J ChouInterdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 201203, Shanghai, China.ORCID http://orcid.org/0000-0002-4442-0344
Donna L SengerArnie Charbonneau Cancer Institute, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, T2N 1N4, Canada.ORCID http://orcid.org/0000-0003-2403-3395
Carlos F IbáñezDepartment of Physiology and Life Sciences Institute, National University of Singapore, Singapore, 117456, Singapore. carlos.ibanez@pku.edu.cn.ORCID http://orcid.org/0000-0003-4090-0794

Funding

Canadian Cancer Society (CCS) n/aCancerfonden (Swedish Cancer Society) 18-0670Cancerfonden (Swedish Cancer Society) 18-0829National Natural Science Fund of China 82350710799NMRC Singapore NMRC/OFIRG/MOH-000224Robert C. Westbury Endowment n/aShanghai Science and Technology Committee Fund 22JC1410500Vetenskapsrådet (VR) 2020-01923
6 · The paper itself

Abstract

Receptor transmembrane domains (TMDs) are crucially involved in relaying ligand information from extracellular to intracellular spaces and represent attractive targets for small molecule manipulation of receptor function. Screening a library of over 8000 drug-like compounds with an assay based on the TMD of death receptor p75

Indexed as

Antineoplastic AgentsCell MovementLung NeoplasmsMelanomaNerve Tissue ProteinsReceptors, Nerve Growth FactorSmall Molecule LibrariesAnimalsCell Line, TumorDisease Models, AnimalHumansMiceMicrofilament ProteinsNeoplasm InvasivenessAntineoplastic AgentsMicrofilament ProteinsNerve Tissue ProteinsNGFR protein, humanReceptors, Nerve Growth FactorSmall Molecule LibrariesAraTMChemical BiologyCytoskeletonLung TumorsMedicinal Chemistry

Identifiers

PMID40962940
PMCPMC12514245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.